drugset / Trial / NCT05053880
A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme
Phase 1/2
Active not recruiting
48 enrolled
Accendatech USA Inc.
Avance Clinical Pty Ltd. · collabC3 Research Associates · collab
RandomizedSequentialOpen-labelTreatment
Summary
The current design provides a window to analyze the impact of the ACT001+Pembrolizumab combination on the tumor microenvironment and disease outcomes.
Timeline
- Start
- 2021-09-22
- Primary completion
- 2024-10-25
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ACT001 | Unknown | 200 mg | Oral |
| Subject | ACT001 | Unknown | 400 mg | Oral |
| Subject | ACT001 | Unknown | 800 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |